World Hepatitis Day 2026 Highlights India's Fight Against Viral Hepatitis and the Goal of Disease Elimination by 2030

Recent Developments:

• The world observed World Hepatitis Day on 28 July 2026 to raise awareness about viral hepatitis, one of the leading causes of infectious disease-related deaths globally.
• The World Health Organization (WHO) announced the 2026 theme, "Hepatitis: Let's Break It Down", emphasising the removal of financial, social and systemic barriers to hepatitis prevention, testing, treatment and care. This year's campaign highlights the need for equitable access to hepatitis services to achieve elimination targets by 2030.

About Hepatitis:

Meaning and Nature:

• Hepatitis refers to inflammation of the liver, primarily caused by viral infections, although alcohol abuse, certain medicines, toxins and autoimmune disorders can also lead to liver inflammation.
• The disease may be acute or chronic, depending upon the duration of infection and the extent of liver damage.
• Chronic liver inflammation can progressively lead to cirrhosis, liver failure and hepatocellular carcinoma (liver cancer).

Major Types of Viral Hepatitis:

• The five principal hepatitis viruses are Hepatitis A (HAV), Hepatitis B (HBV), Hepatitis C (HCV), Hepatitis D (HDV) and Hepatitis E (HEV).
• Hepatitis B and Hepatitis C together account for more than 90% of deaths and long-term disability associated with viral hepatitis.
• Hepatitis D occurs only in individuals already infected with Hepatitis B, making HBV vaccination the most effective preventive strategy against both infections.

Global and Indian Burden of Hepatitis:

Global Scenario:

• Viral hepatitis causes nearly 1.3 million deaths and approximately 2 million new infections every year worldwide.
• Around 287 million people are living with chronic Hepatitis B or Hepatitis C, while a majority remain undiagnosed because of the absence of early symptoms.
• The WHO Global Health Sector Strategy 2022–2030 aims to eliminate viral hepatitis as a public health threat by 2030.

India's Disease Burden:

• India has nearly 29 million people living with chronic Hepatitis B and about 5.5 million people with chronic Hepatitis C, making it one of the countries with the highest hepatitis burden globally.
• India contributes nearly 10–15% of the global Hepatitis B carrier population.
• According to India HIV Sentinel Surveillance 2021, Hepatitis B seroprevalence is approximately 0.85%, whereas Hepatitis C seroprevalence is around 0.29%.

Meaning of Seroprevalence:

• Seroprevalence refers to the proportion of individuals in a surveyed population who test positive for disease-specific antibodies or antigens, indicating present or past infection.

Clinical Features and Public Health Challenges:

Common Symptoms:

• Most infected individuals remain asymptomatic during the early stages of infection.
• Clinical manifestations may include persistent fatigue, loss of appetite, nausea, abdominal discomfort, dark-coloured urine and jaundice.

Diagnosis and Vaccination Gaps:

• India's Hepatitis B diagnosis rate remains close to 2.4%, indicating that most infected individuals have never undergone testing.
• The birth-dose Hepatitis B vaccine presently reaches only around 63% of newborns, although completion of the childhood vaccination schedule is significantly higher.
• Delay in administering the birth dose substantially increases the risk of mother-to-child transmission.

Major Barriers:

• Low public awareness and widespread misinformation delay timely diagnosis.
• Social stigma discourages individuals from seeking testing and treatment.
• Weak integration of hepatitis services into primary healthcare reduces accessibility.
• High treatment costs continue to affect equitable healthcare utilisation.

Transmission, Prevention and Management of Different Types of Hepatitis:

Hepatitis A and Hepatitis E:

• Cause, Infection with HAV or HEV.
• Transmission, Contaminated food or water through the faecal-oral route, poor sanitation and unsafe drinking water.
• Prevention, Safe drinking water, improved sanitation, personal hygiene and Hepatitis A vaccination.
• Treatment, Supportive care including adequate hydration and nutrition, as no specific antiviral therapy is generally required.

Hepatitis B:

• Cause, Infection with HBV.
• Transmission, Mother-to-child transmission during childbirth, infected blood, blood products and body fluids.
• Prevention, Universal Hepatitis B vaccination, birth dose within 24 hours, subsequent doses at 6, 10 and 14 weeks, safe injection practices and screened blood transfusion.
• Treatment, Eligible chronic patients receive antiviral medicines according to national treatment guidelines.

Hepatitis C:

• Cause, Infection with HCV.
• Transmission, Exposure to infected blood through unsafe injections, contaminated medical procedures, shared needles and infected blood products.
• Prevention, Safe injections, screened blood transfusion and harm-reduction measures such as needle-exchange programmes, while no vaccine is currently available.
• Treatment, Nearly all patients can be cured within 12–24 weeks using pan-genotypic Direct-Acting Antiviral (DAA) medicines.

Hepatitis D:

• Cause, Infection with HDV, occurring only among individuals already infected with HBV.
• Transmission, Contact with infected blood, blood products and body fluids.
• Prevention, Hepatitis B vaccination effectively prevents Hepatitis D infection.
• Treatment, Management primarily focuses on specialist care and effective treatment of the underlying Hepatitis B infection.

Government Initiatives for Hepatitis Control:

National Viral Hepatitis Control Programme (NVHCP):

• The National Viral Hepatitis Control Programme was launched in 2018 to provide integrated screening, diagnosis, treatment and long-term management of viral hepatitis.
• The programme supports the achievement of the Sustainable Development Goals (SDGs) relating to communicable disease elimination by 2030.
• The programme covers Hepatitis A, B, C, D and E through preventive, promotive and curative interventions.
• Hepatitis A and Hepatitis E outbreaks are monitored through the Integrated Disease Surveillance Programme (IDSP).
• Free diagnostic services and medicines are provided for eligible Hepatitis B and Hepatitis C patients.
• The programme utilises the NVHCP Management Information System (MIS) for digital patient registration, treatment monitoring and programme management.

Other Supporting National Health Programmes:

Integrated National Efforts:

• The Reproductive, Maternal, Newborn, Child, Adolescent Health and Nutrition (RMNCAH+N) strategy provides universal screening of pregnant women for Hepatitis B.
• The Universal Immunisation Programme (UIP) ensures administration of the Hepatitis B birth dose, while newborns of infected mothers also receive Hepatitis B Immunoglobulin (HBIG) within 24 hours of birth.
• The National AIDS Control Programme (NACP) supports screening of high-risk groups and provides Hepatitis B vaccination to healthcare workers and eligible vulnerable populations.
• Existing molecular diagnostic platforms under the National Tuberculosis Elimination Programme (NTEP) are utilised for hepatitis diagnosis wherever feasible.
• Blood Transfusion Services ensure linkage of hepatitis-positive blood donors with appropriate healthcare facilities.
• The toll-free 1800-11-6666 helpline provides information regarding hepatitis prevention, diagnosis, treatment and service availability across India.

WHO Elimination Targets for 2030:

Global Targets:

• Achieve a 90% reduction in new Hepatitis B infections.
• Achieve a 65% reduction in hepatitis-related mortality.
• Ensure 90% diagnosis coverage among infected individuals.
• Expand access to affordable testing, vaccination and antiviral treatment under Universal Health Coverage (UHC).

Way Forward:

Priority Interventions:

• Expand awareness campaigns to improve early diagnosis and reduce stigma.
• Strengthen integration of hepatitis services within primary healthcare systems.
• Improve universal birth-dose vaccination coverage and timely immunisation.
• Increase affordable access to diagnostics, antiviral medicines and long-term follow-up services.
• Strengthen disease surveillance, digital monitoring and community-level screening for high-risk populations.

Value Addition for UPSC:

Important Facts for Prelims and Mains:

• World Hepatitis Day: 28 July every year, commemorating the birth anniversary of Dr. Baruch Samuel Blumberg, discoverer of the Hepatitis B virus, developer of the first Hepatitis B vaccine and recipient of the 1976 Nobel Prize in Physiology or Medicine.
• 2026 Theme: "Hepatitis: Let's Break It Down."
• Target Organ: Liver.
• Only Vaccine-Preventable Major Viral Hepatitis: Hepatitis A and Hepatitis B.
• No Licensed Vaccine Available: Hepatitis C.
• Hepatitis D Dependency: Infection occurs only in individuals already infected with Hepatitis B.
• National Programme: National Viral Hepatitis Control Programme (2018).
• WHO Elimination Goal: Eliminate viral hepatitis as a public health threat by 2030.
• Most Common Causes of Hepatitis-Related Deaths: Cirrhosis and Hepatocellular Carcinoma (Liver Cancer)